Announcement on Provision for Asset Impairment in Q1 2025
Filed with SSE · · 2 pages · Chinese
Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. on 6ix
Earlier from Beijing Wantai Biological Pharmacy Enterprise
- Announcement on Convening the 2024 Annual and Q1 2025 Performance and Cash Dividend Briefing
- Announcement on Initiating Phase III Clinical Trial of 9-valent HPV Vaccine for Men and Completing the Enrollment of First Subject
- Special Report on Annual Deposit and Actual Use of Raised Funds in 2024
- Announcement on Inclusion of TB Specific T-cell Detection Kit EpiDot.TB (Enzyme-linked Immunosorbent Assay for In Vitro Release) into the Purchase Order of United Nations Office for Project Services
- Announcement on Opening a Special Account for Wealth Management and Signing a Tripartite Supervision Agreement for the Special Account of Raised Funds
Later from Beijing Wantai Biological Pharmacy Enterprise
- Announcement on HIV Antibody Urine Self-Test Reagent Passing WHO PQ Certification
- Announcement on Resolution of the 2024 Annual General Meeting
- Announcement on Result of Share Reduction by Shareholder through Call Auction
- Announcement on Approval of the Application for Marketing Authorization of 9-valent HPV Vaccine
- Announcement on Redemption at Maturity of Some Idle Raised Funds Used for Cash Management
Follow Beijing Wantai Biological Pharmacy Enterprise into a list and get an email when it puts out news.
Follow Beijing Wantai Biological Pharmacy Enterprise